Wilder,
Listened to the MCLS conference call. I'm confused on a couple of points regarding objectives and cash burn, so I'll probably have to listen again and maybe call IR myself. I will update in detail when that's resolved. For now, per a previous post, bottom line is that . . .
>>Naturally, they have to execute and score a win or two in the next year, and if they didn't it might be time to bail.<<
They report that they are in "substantive talks." Mostly in structural proteomics (but also in biocatalysis) & chiefly with existing customers, but with a difference. Especially with respect to proteomics, they are being checked out by higher level pharma managers than usual. SVPs. FWIW. They've beefed up and if they don't get results from that, they will need to dilute. However, they are trading for roughly the replacement cost of the new facility (across the street from Argonne, BTW) and cash.
They might do an acquisition in ADME-tox. They note several emerging companies with good cash flow, such that financing the munch with a stock swap would be accretive.
They mentioned advantages in crystallizing GPCR-related and membrane bound proteins? Does that give you a hint on the other 39? Since they are in talks about this stuff, your email might go unanswered.
Not a long Q&A, but analysts from well known companies on the call, so it seems as though interest is building.
Per my threat, Trickle will munch another 1000 (it happens to be 1.75 again), and give them two Qs to come up with a strategic deal.
Trickle notes EBIO is up hard on no news. We'll take it.
Mass spec companies have resisted the CapEx slowdown better than most expected, resulting in a nice recovery for WAT. Trickle will sell 100 shares for four reasons. 1) Trickle feels we're in for a near-term pullback, if not a retest of March 22 lows. 2) WAT's improved fundamental outlook should be largely repriced in by now. 3) Trickle wants dry powder for the expected pull-back, and 1/2 of WAT holding is a good source. 4) Trickle has plenty of mass spec exposure. 100 shares at $56.
Cheers, Tuck |
